Sg Americas Securities, LLC Kymera Therapeutics, Inc. Transaction History

Sg Americas Securities, LLC

$27.6 Billion
Q3 2024

A detailed history of Sg Americas Securities, LLC transactions in Kymera Therapeutics, Inc. stock. As of the latest transaction made, Sg Americas Securities, LLC holds 14,719 shares of KYMR stock, worth $617,609. This represents 0.0% of its overall portfolio holdings.

Number of Shares

14,719

Previous 10,887 35.2%

Holding current value

$617,609

Previous $325,000 114.46%

% of portfolio

0.0%

Previous 0.0%

12 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q3 2024 Oct 03, 2024	BUY	$30.16 - $52.4 $115,573 - $200,796	3,832 Added 35.2%	14,719 $697,000
Q2 2024 Jul 12, 2024	BUY	$29.85 - $39.42 $206,979 - $273,338	6,934 Added 175.41%	10,887 $325,000
Q1 2024 May 06, 2024	SELL	$22.9 - $43.57 $334,569 - $636,557	-14,610 Reduced 78.7%	3,953 $159,000
Q4 2023 Jan 12, 2024	BUY	$10.97 - $26.84 $203,636 - $498,230	18,563 New	18,563 $473,000
Q1 2023 Apr 28, 2023	BUY	$24.84 - $38.75 $217,896 - $339,915	8,772 New	8,772 $260,000
Q3 2022 Oct 31, 2022	SELL	$20.91 - $34.27 $600,451 - $984,097	-28,716 Reduced 76.89%	8,629 $188,000
Q2 2022 Jul 29, 2022	BUY	$14.13 - $42.55 $428,153 - $1.29 Million	30,301 Added 430.17%	37,345 $735,000
Q1 2022 Apr 29, 2022	SELL	$35.3 - $64.68 $124,679 - $228,449	-3,532 Reduced 33.4%	7,044 $298,000
Q4 2021 Feb 07, 2022	SELL	$49.91 - $65.56 $315,780 - $414,798	-6,327 Reduced 37.43%	10,576 $671,000
Q3 2021 Nov 01, 2021	BUY	$47.8 - $66.66 $639,611 - $891,977	13,381 Added 379.93%	16,903 $993,000
Q2 2021 Aug 12, 2021	SELL	$31.08 - $51.95 $15,167 - $25,351	-488 Reduced 12.17%	3,522 $171,000
Q1 2021 May 13, 2021	BUY	$35.64 - $85.46 $142,916 - $342,694	4,010 New	4,010 $156,000

Others Institutions Holding KYMR

# of Institutions

184

Shares Held

64.4M

Call Options Held

50.6K

Put Options Held

81.7K

View Full List

About Kymera Therapeutics, Inc.

Ticker KYMR
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 54,705,800
Market Cap $2.3B
Description
Kymera Therapeutics, Inc., a biopharmaceutical company, focuses on discovering and developing novel small molecule therapeutics that selectively degrade disease-causing proteins by harnessing the body's own natural protein degradation system. It engages in developing IRAK4 program, which is in Phase I clinical trial for the treatment of immunolo...

More about KYMR

Track This Portfolio

Portfolio Update

Get notified when there are updates to the investment portfolio of Sg Americas Securities, LLC, based on Form 13F filings with the SEC.

News

Stay updated on Sg Americas Securities, LLC with notifications on news.

Account

Sg Americas Securities, LLC Kymera Therapeutics, Inc. Transaction History